X
AUPH icon

Xponance’s Aurinia Pharmaceuticals AUPH Stock Holding History

Xponance’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$199K Buy
11,707
+760
+7% +$12.1K ﹤0.01% 1613
2026
Q1 		$162K Buy
+10,947
New +$160K ﹤0.01% 1506
2025
Q2 		– Sell
-10,146
Closed -$81.6K – 1511
2025
Q1 		$81.6K Buy
+10,146
New +$82.2K ﹤0.01% 1366

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Xponance's AUPH Position: Q2 2026 in Review

Xponance increased its Aurinia Pharmaceuticals (AUPH) stake by 6.9% in Q2 2026, buying an estimated $12.1K and bringing the position to 11,707 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #1613.

Xponance first reported a position in AUPH in Q1 2025 and has held it in 3 quarters since. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Xponance held 11,707 shares of Aurinia Pharmaceuticals worth $199K as of Q2 2026.
  • Xponance bought 760 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $12.1K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1613 holding.
  • Xponance first reported a position in Aurinia Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.